FVFritz-Line Vélayoudom-Céphise

Fritz-Line Vélayoudom-Céphise

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fritz-Line Vélayoudom-Céphise has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Laurent Larifla

    Research Team on Cardiometabolic Risk ECM, University Hospital, University of the Antilles, 97157 Pointe-à-Pitre, Guadeloupe, France

    3 shared publications
  • Lydia Foucan

    Research Team on Cardiometabolic Risk ECM, University Hospital, University of the Antilles, 97157 Pointe-à-Pitre, Guadeloupe, France

    3 shared publications
  • Jacques Ducros

    Centre de dialyse AUDRA, Hôpital RICOU, Pointe-À-Pitre, Guadeloupe France ; Service de Néphrologie, Centre Hospitalier Universitaire, Pointe-à-Pitre, Guadeloupe France

    2 shared publications
  • André Atallah

    Service de cardiologie, réseau HTA-GWAD.Gip.Raspeg. Guadeloupe, centre hospitalier de Basse-Terre, 97100 Basse-Terre, Guadeloupe

    1 shared publication
  • Anne Blanchet-Deverly

    Cardiology Unit, University Hospital of Pointe-à-Pitre, Guadeloupe, French West Indies, France

    1 shared publication
  • Antoine Tabarin

    Department of Endocrinology, USN Haut-Lévêque, 33604, Pessac, France

    1 shared publication

Latest Publications

  • Open Access

    Skin autofluorescence predicts cardio-renal outcome in type 1 diabetes: a longitudinal study

    by Fritz-Line Vélayoudom-Céphise, Kalina Rajaobelina, Catherine Helmer, Sovanndany Nov, Emilie Pupier, Laurence Blanco, Marie Hugo, Blandine Farges, Cyril Astrugue, Henri Gin, et al.

    We aimed to analyze the relationships between skin autofluorescence (SAF) and incident macrovascular events and renal impairment after 4 years of follow-up in patients with type 1 diabetes (T1D). Two hundred and forty-three patients (51.2 ± 16.7 years old) with T1D participated. SAF was measured by AGE-Reader-TM at inclusion. Macrovascular events (MVE), estimated glomerular filtration rate (eGFR) and urinary albumin excretion rate (AER) were recorded then and 4 years later. Multivariate logistic regression was used to analyze the relationships between SAF and incident MVE and renal profile 4 years later. Patients with incident MVE had a higher SAF (p = 0.003). SAF predicted incident MVE after adjustment for age, sex, body mass index, tobacco, diabetes duration, hypertension, HbA1c, AER, eGFR (OR 4.84 [95 % CI 1.31–17.89], p = 0.018). However, this relation was no longer significant after adjustment for history of MVE. An inverse relation was found between SAF and incident eGFR (p = 0.0001). Patients with incident eGFR 2 had a SAF higher than patients with normal eGFR. After adjustment for the previous criteria, SAF remained associated with the risk of impaired incident eGFR (OR 7.42 [95 % CI 1.59–34.65], p = 0.018). No relation was found between SAF and increased AER 4 years later. SAF predicts MVE in patients with T1D, adjusted for cardiovascular risk factors but the most powerful predictive factor remains history of MVE. SAF also predicts eGFR impairment, adjusted for initial AER and renal function. SAF could be a useful non-invasive tool for estimating risk of cardiovascular or renal impairment in patients with T1D.


  • CA-056: L'autofluorescence cutanée prédit la fonction rénale à 4 ans chez le diabétique de type 1

    by F. Velayoudom-Cephise, K. Rajaobelina, C. Helmer, C. Astrugue, S. Nov, M. Hugo, L. Blanco, B. Farges, H. Gin, V. Rigalleau

  • Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1

    by Clément Morgat, Fritz-Line Vélayoudom-Céphise, Paul Schwartz, Martine Guyot, Delphine Gaye, Delphine Vimont, Jürgen Schulz, Joachim Mazère, Marie-Laure Nunes, Denis Smith, et al.

    Context Somatostatin receptor scintigraphy with 111In-pentetreotide (SRS) is used to detect duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). However, SRS has limited sensitivity for this purpose. Positron emission tomography/computed tomography (PET/CT) with 68Ga-DOTA-TOC has a higher rate of sporadic dpNETs detection than SRS but there is little data for dpNETs detection in MEN1. Purpose To compare the performances of 68Ga-DOTA-TOC PET/CT, SRS and contrast-enhanced computed tomography (CE-CT) to diagnose dpNETs in MEN1. Design and setting Single-institution prospective comparative study Patients and methods Nineteen consecutive MEN1 patients (aged 47 ± 13 years) underwent 68Ga-DOTA-TOC PET/CT, SRS, and CE-CT within 2 months in random order. Blinded readings of images were performed separately by experienced physicians. Unblinded analysis of CE-CT, combined with additional magnetic resonance imaging, endoscopic-ultrasound, 18F-2-fluoro-deoxy-d-glucose (18F-FDG) PET/CT or histopathology results served as reference standard for dpNETs diagnosis. Results The sensitivity of 68Ga-DOTA-TOC PET/CT, SRS, and CE-CT was 76, 20, and 60 %, respectively (p < 0.0001). All the true-positive lesions detected by SRS were also depicted on 68Ga-DOTA-TOC PET/CT. 68Ga-DOTA-TOC PET/CT detected lesions of smaller size than SRS (10.7 ± 7.6 and 15.2 ± 5.9 mm, respectively, p < 0.03). False negatives of 68Ga-DOTA-TOC PET/CT included small dpNETs (18F-FDG PET/CT positive aggressive dpNETs. No false positives were recorded. In addition, whole-body mapping with 68Ga-DOTA-TOC PET/CT identified extra-abdominal MEN1-related tumors including one neuroendocrine thymic carcinoma identified by the three imaging procedures, one bronchial carcinoid undetected by CE-CT and three meningiomas undetected by SRS. Conclusions Owing to higher diagnostic performance, 68Ga-DOTA-TOC PET/CT (or alternative 68Ga-labeled somatostatin analogues) should replace 111In-pentetreotide in the investigation of MEN1 patients.


  • Traitement du syndrome de Cushing par hyperplasie macronodulaire primaire : bénéfices cliniques de la surrénalectomie unilatérale

    by E. Debillon, F.L. Velayoudom-Cephise, S. Salenave, P. Caron, M. Benoit, J. Young, A. Tabarin, O. Chabre

  • Open Access

    Impact of protein energy wasting status on survival among Afro-Caribbean hemodialysis patients: a 3-year prospective study

    by Lydia Foucan, Henri Merault, Fritz-Line Velayoudom-Cephise, Laurent Larifla, Cosmin Alecu, Jacques Ducros

    We assessed the prognostic value of protein-energy wasting (PEW) on mortality in Afro-Caribbean MHD patients and analysed how diabetes, cardiovascular disease (CVD) and inflammation modified the predictive power of a severe wasting state. A 3-year prospective study was conducted in 216 patients from December 2011. We used four criteria from the nomenclature for PEW proposed by the International Society of Renal Nutrition and Metabolism in 2008: serum albumin 38 g/L, body mass index (BMI) ≤23 kg/m2, serum creatinine ≤818 µmol/L and protein intake assessed by nPCR ≤0.8 g/kg/day. PEW status was categorized according the number of criteria. Cox regression analyses were used. Forty deaths (18.5 %) occurred, 97.5 % with a CV cause. Deaths were distributed as follows: 7.4 % in normal nutritional status, 13.2 % in slight wasting (1 PEW criterion), 28 % in moderate wasting (2 criteria) and 50 % in severe wasting (3–4 criteria). Among the PEW markers, low serum albumin (HR 3.18; P = 0.001) and low BMI (HR 1.97; P = 0.034) were the most significant predictors of death. Among the PEW status categories, moderate wasting (HR 3.43; P = 0.021) and severe wasting (HR 6.59; P = 0.001) were significant predictors of death. Diabetes, CVD, and inflammation were all additives in predicting death in association with severe wasting with a strongest HR (7.76; P < 0.001) for diabetic patients. The nomenclature for PEW predicts mortality in our Afro-Caribbean MHD patients and help to identify patients at risk of severe wasting to provide adequate nutritional support.


  • Open Access

    Polymorphisms in GC and NADSYN1 Genes are associated with vitamin D status and metabolic profile in Non-diabetic adults

    by Lydia Foucan, Fritz-Line Vélayoudom-Céphise, Laurent Larifla, Christophe Armand, Jacqueline Deloumeaux, Cedric Fagour, Jean Plumasseau, Marie-Line Portlis, Longjian Liu, Fabrice Bonnet, et al.

    Our aim was to assess the associations between vitamin D (vitD) status, metabolic profile and polymorphisms in genes involved in the transport (Group-Component: GC) and the hydroxylation (NAD synthetase 1: NADSYN1) of 25 hydroxyvitamin D (25(OH)D) in non-diabetic individuals.


  • Rachitisme hypophosphatémique lié à l’X ou dysplasies spondylo-métaphysaires de Schmidt : piège clinique possible

    by M. Popescu, C. Guinchard, A. Rothenbuhler, C. Messerschmitt, F.-L. Velayoudom-Cephise

  • Open Access

    Association of 2238T>C Polymorphism of the Atrial Natriuretic Peptide Gene With Coronary Artery Disease in Afro-Caribbeans With Type 2 Diabetes

    by Laurent Larifla, Suriya Maimaitiming, Fritz-Line Velayoudom-Cephise, Severine Ferdinand, Anne Blanchet-Deverly, Sonia BenAbdallah, Jean-Paul Donnet, André Atallah, Ronan Roussel, Lydia Foucan

    Background. The atrial natriuretic peptide (ANP) is known mainly for its effects on kidney function and blood pressure homeostasis. We investigated the